David F McDermott

25PUBLICATIONS
185CO-AUTHORS
Molecular targetsBiologically active moleculesCancer therapy (excl. chemotherapy and radiation therapy)Predictive and prognostic markersComparative religious studies
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (25)

|May 18, 2026
Dissecting the Tumor Microenvironment to Identify Biomarkers of Outcome to Anti-PD-1 Therapy in Clear Cell Renal Cell Carcinoma: analyses of the HCRN GU16-260 trial.

|Apr 28, 2026
The clinical landscape of HIF2α inhibitors in oncology.

|Dec 13, 2025
Advanced Urologic Cancer Consensus Conference (AUC3) 2025: Expert consensus on the management of renal cell and urinary tract cancers.

Rana R McKay, Sumanta Pal, Wanling Xie

|Sep 12, 2025
Analysis of treatment-free survival of patients with advanced melanoma receiving nivolumab as monotherapy or in combination with relatlimab in RELATIVITY-047.

Meredith M Regan, Paolo A Ascierto, Evan J Lipson

|Jul 14, 2025
Long-Term Performance of Prognostic Models for Advanced Renal Cell Carcinoma in the Era of Improved Survival With Immune Checkpoint Inhibitors.

Charlene M Mantia, Opeyemi A Jegede, David F McDermott

|Jul 02, 2025
Tumor-Intrinsic and Microenvironmental Determinants of Impaired Antitumor Immunity in Chromophobe Renal Cell Carcinoma.

Chris Labaki, Eddy Saad, Katrine N Madsen

Pageof 5

Frequent Collaborators

15 joint publications

Toni K Choueiri

10 joint publications

David Braun

8 joint publications

Michael B Atkins

7 joint publications

Wanling Xie